Antihypertensive and vasoprotective effectiveness of the chronopharmacotherapy in patients with arterial hypertension after acute cerebrovascular accident

Aim. To evaluate the effectiveness of combined antihypertensive chronopharmacotherapy and estimate the daily blood pressure profle (BP) parameters, such as: stiffness of the vascular wall and central aortic pressure in patients with arterial hypertension (AH) who underwent transient ischemic atack (TIA) or ischemic stroke (IS).

Materials and methods. 235 patients with hypertension who underwent acute cerebrovascular accident were examined. Tere were 116 patients with TIA and 119 with IS. All patients were randomized in 4 groups according to regimen of antihypertensive drugs combination. Te 1st group (n = 59) included patients with AH, who underwent TIA and received indapamide retard 1.5 mg and valsartan 160 mg in the morning regiment of drug therapy. Te 2nd group (n = 57) included patients with AH, who underwent TIA and received indapamide retard 1.5 mg in the morning and valsartan 80 mg twice a day (morning and evening). Te 3rd group (n = 47) included patients with AH, who underwent IS and received indapamide retard 1.5 mg and valsartan at a dose of 160 mg in the morning. Te 4th group (n = 56) included patients with AH, who underwent IS and received indapamide retard 1.5 mg in the morning and valsartan 80 mg twice a day (morning and evening). Ambulatory blood pressure monitoring (ABPM), central aortic pressure (CAP) measurement and vessel wall stiffness values were evaluated before treatment and afer 12 months of therapy.

Results. Before the start of combined antihypertensive chronopharmacotherapy, most of the parameters for ABPM, vessel wall stiffness values and CAP in groups 1 and 2, 3 and 4 were comparable. Achievement of the target level of BP afer 8 weeks of treatment, was signifcantly more ofen in groups with a double sartan therapy (group 2 and group 4) in compare with its single time application only in the morning hours (group 1 and group 3) (p<0.05). Statistically signifcant positive dynamics of the main values of the daily profle of blood pressure, stiffness of the vascular wall and central aortic pressure (p <0,05) were registered in all groups. However, more pronounced decline of main parameters of ABPM, stiffness of the vascular wall and central aortic pressure values were noted in group with double use sartan therapy in compare with single time sartan therapy in the morning time. (p <0.05). Signifcant positive dynamics of the main values of the ABPM, stiffness of the vascular wall and CAP were registered in patients who underwent IS and received double application sartan therapy (4th group) in compare with patients with TIA (2nd group) (p = 0.02).

Conclusion. Double use sartan therapy, combined with a thiazide diuretics in patients, who underwent IS or TIA more ofen promotes to get target values of blood pressure, improve the main values of the ABPM, stiffness of the vascular wall and CAP in compare with single time sartan therapy in the morning time

1. Soliman RH, Oraby MI, Fathy M, Essam AM. Risk factors of acute ischemic stroke in patients presented to Beni-Suef University Hospital: prevalence and relation to stroke severity at presentation. Te Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2018;54(1). DOI: 10.1186/s41983-018-0012-4

2. Shu J-E, Ying M-L, Chen X-R, Hua J-J, Fu J-T, Xia X-M et al. Prognostic value of high-resolution magnetic resonance imaging in evaluating carotid atherosclerotic plaque in patients with ischemic stroke: Medicine. 2017;96(45):e8515. DOI: 10.1097/MD.0000000000008515

3. Roman MJ, Okin PM, Kizer JR, Lee ET, Howard BV, Devereux RB. Relations of central and brachial blood pressure to lef ventricular hypertrophy and geometry: the Strong Heart Study: Journal of Hypertension. 2010;28(2):384–8. DOI: 10.1097/HJH.0b013e328333d228

4. Kwarciany M, Gąsecki D, Kowalczyk K, Rojek A, Laurent S, Boutouyrie P et al. Acute hypertensive response in ischemic stroke is associated with increased aortic stiffness. Atherosclerosis. 2016;251:1–5. DOI: 10.1016/j.atherosclerosis.2016.04.027

5. Geraskina L. A., Fonyakin A. V. Endothelial function, elastic properties of the vascular wall in hypertensive ischemic cerebrovascular diseases. Annals of Clinical and Experimental Neurology. 2009;3(2):4-8.

6. Nedogoda S. V., Ledyaeva A. A., Chumachek E. V., Barykina I. N. Central pressure in the aorta as a target for antihypertensive therapy. Pharmateka. 2011;20:30-7.

7. Zyryanov S. K., Butranova O. I. Antihypertensive therapy: From clinical pharmacology to clinical outcome. Or what is important to know when choosing an antihypertensive drug. Russian Heart Journal. 2017;16(4):286–96.

8. Skibitsky V. V., Fendrikova A. V., Opolskaya S. V. Comparison of influence of drag intake on 24 hour blood pressure? Central aortic pressure and vascular wall stiffness in systemic hypertension patients with ischemic stroke. Russian Journal of Cardiology. 2018;23(4):56-66.DOI: 10.15829/1560-4071-2018-4-56-66

9. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy Improves Blood Pressure Control and Reverts the Nondipper Patern in Patients with Resistant Hypertension. Hypertension. 2008;51(1):69– 76. DOI: 10.1161/HYPERTENSIONAHA.107.096933

10. Smolensky MH, Hermida RC, Ayala DE, Portaluppi F. Bedtime hypertension chronotherapy: concepts and patient outcomes. Current Pharmaceutical Design. 2015;21(6):773–90. PMID: 25341856

11. Kotovskaya Yu. V., Semagina I. M., Kobalava Zh. D. A comparative analysis of the daily profle of arterial pressure in the brachial artery and aorta with simultaneous monitoring in patients with untreated arterial hypertension. Arterial Hypertension. 2015;21(6):567-76.

12. Hermida RC, Calvo C, Ayala DE, Fernández JR, Covelo M, Mojón A et al. Treatment of non-dipper hypertension with bedtime administration of valsartan: Journal of Hypertension. 2005;23(10):1913–22. DOI: 10.1097/01.hjh.0000182522.21569.c5

13. Podzolkov V. I., Dragomiretskaya N. A. Choice of Angiotensin Receptor Blocker at Various Stages of the Cardiovascular Continuum. Kardiologiia. 2017;57(10):45-55. DOI: 10.18087/cardio.2017.10.10042

14. Leonova M. V. Clinical pharmacology of AT II receptor blockers: valsartan. Medical Council. 2014;17:66-71.

15. Levin Ya. I. Melatonin and cerebrovascular diseases. RMJ. 2008;16(26):1732-4.

16. Nedogoda S. V., Smirnova V. O., Barykina I. N., Salasyuk A. S., Khripaeva V. Yu., Palashkin R. V., Popova E. A. Te effect of melatonin therapy on endothelial function, blood pressure and vascular stiffness in patients with metabolic syndrome and sleep disorders. Arterial hypertension. 2017;23(2):150–9.